{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.0","value":"63.2"},{"groupId":"OG001","spread":"10.8","value":"51.6"},{"groupId":"OG002","spread":"13.6","value":"57.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.7","value":"58.7"},{"groupId":"OG001","spread":"13.3","value":"55.5"},{"groupId":"OG002","spread":"11.1","value":"54.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Prior to Maintenance Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.9","value":"60.8"},{"groupId":"OG001","spread":"11.1","value":"54.9"},{"groupId":"OG002","spread":"16.8","value":"49.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Completion of Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.1","value":"64.4"},{"groupId":"OG001","spread":"14.5","value":"60.4"},{"groupId":"OG002","spread":"22.3","value":"67.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"12 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.8","value":"63.6"},{"groupId":"OG001","spread":"14.7","value":"59.4"},{"groupId":"OG002","spread":"13.3","value":"55.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"24 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.9","value":"59.3"},{"groupId":"OG001","spread":"14.2","value":"62.0"},{"groupId":"OG002","spread":"8.6","value":"61.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"36 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.1","value":"60.9"},{"groupId":"OG001","spread":"13.1","value":"60.0"},{"groupId":"OG002","spread":"12.8","value":"54.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"48 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.3","value":"56.8"},{"groupId":"OG001","spread":"14.3","value":"60.6"},{"groupId":"OG002","spread":"15.3","value":"61.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"60 Months Off Therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"Scores measuring working memory were obtained from Working Memory T-scores, which were obtained from the Behavior Rating Inventory of Executive Function (BRIEF) instrument which is a parent report. Higher scores indicate more problems. The normative mean is 50 with a standard deviation of 10.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy","title":"Neurocognitive Performance Related to Working Memory as Measured by Working Memory T-scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}